Arbutus Biopharma Corp (ABUS)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

100-8900 GLENLYON PARKWAY BURNABY, BRITISH COLUMBIA, CANADA V5J 5J8

Tekmira Pharmaceuticals Corporation a biopharmaceutical company develops and commercializes proprietary drugs and drug delivery systems for the treatment of cancer and other diseases.

Data as of 2020-08-09
Market Cap262.053 Million Shares Outstanding68.961 Million Avg 30-day Volume15.985 Million
P/E Ratio Dividend Yield EPS-2.67
Price/Sales42.472 Price cash flow ratio7665.1 Price free cash flow ratio-5.0
Book Value-0.97 Price to Tangible Book-3.91 Alpha-0.0
Short Interest Ratio % Short Interest to Float R-squared0.218074
BETA3.14316 52-week High/Low9.02 / 0.8214 Stddev0.283035
View SEC Filings from ABUS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 48 18 (1.18%)
Aggregate 13F shares on 03/31/2020: 28.059 Million 14.113 Million
Aggregate 13F shares on 12/31/2019: 24.263 Million 13.192 Million
Percent change: 15.65% 6.98%
Funds creating new positions: 9 5
Funds Adding to an existing position: 18 7
Funds closing out their position: 18 8
Funds reducing their position: 10 4
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ABUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABUS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

20 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KOWALSKI MARK CHIEF MEDICAL OFFICER

  • Officer
0 2020-08-12 0

BURGESS DANIEL D

  • Director
53,500 2020-07-29 2

MCELHAUGH MICHAEL J. CHIEF BUSINESS OFFICER

  • Officer
1,367,457 2020-07-23 2

KISNER DANIEL L

  • Director
10,000 2020-07-21 0

POTTER MYRTLE S

  • Director
21,480 2020-07-21 1

HASTINGS DAVID C

  • Director
0 2020-07-06 1

CONRAD HERBERT J

  • Director
4,454,566 2020-06-23 0

LO ANDREW

  • Director
0 2020-06-23 0

MACHADO PATRICK

  • Director
0 2020-06-23 0

MEYERS JAMES R

  • Director
0 2020-06-17 2

PHILLIPS PEGGY V

  • Director
0 2020-05-28 0

HENRIQUES RICHARD C JR

  • Director
0 2020-05-28 2

MANCHESTER KEITH S

  • Director
0 2020-05-28 2

TORTI FRANK

  • Director
0 2020-05-28 2

COLLIER WILLIAM H. PRESIDENT AND CEO

  • Officer
  • Director
0 2020-05-28 2

CHENG ANDREW

  • Director
0 2020-05-28 3

ROIVANT SCIENCES LTD.

  • 10% Owner
47,213,419 2020-05-12 0

KARBE FRANK

  • Director
0 2020-05-05 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • 10% Owner
33,333,333 2020-04-28 0

VENKER ERIC

  • Director
0 2020-02-18 1

SOFIA MICHAEL J. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-02-17 1

HOWARD ELIZABETH CHIEF COMPLIANCE OFFICER

  • Officer
0 2020-02-17 1

PICCHIO GASTON CHIEF DEVELOPMENT OFFICER

  • Officer
0 2020-02-17 1

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • Director
  • 10% Owner
  • SEE REMARKSSEE REMARKS
0 2019-07-10 0

SVF INVESTMENTS (UK) LTD

SOFTBANK VISION FUND L.P.

SVF GP (JERSEY) LTD

SVF HOLDINGS (UK) LLP

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
0 2019-07-10 0

DEXXON HOLDINGS LTD.

DEXCEL PHARMA TECHNOLOGIES LTD.

OREN DAN

  • SEE REMARKSSEE REMARKSSEE REMARKS
0 2019-07-10 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING GLOBAL EQUITIES MASTER LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

HALVORSEN OLE ANDREAS

OTT DAVID C.

SHABET ROSE SHARON

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
0 2019-07-10 0

MURRAY MARK J. PRESIDENT AND CEO

  • Officer
  • Director
0 2019-03-01 0

VIKING GLOBAL EQUITIES MASTER LTD.

  • 10% Owner
22,703,669 2019-01-01 0

VANDENENDEN KOERT CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-12-11 0

VIKING GLOBAL PERFORMANCE LLC

VIKING GLOBAL EQUITIES LP

VIKING GLOBAL EQUITIES II LP

VGE III PORTFOLIO LTD.

VIKING LONG FUND GP LLC

VIKING LONG FUND MASTER LTD.

  • 10% Owner
22,703,669 2018-10-01 0

RAMASWAMY VIVEK

  • Director
0 2018-06-19 0

SYMONDS WILLIAM T. CHIEF DEVELOPMENT OFFICER

  • Officer
0 2018-04-16 0

LUTWYCHE PETER FORMER CHIEF TECH. OFFICER

  • Officer
No longer subject to file 2018-04-11 0

COUSINS BRUCE EXEC VO & CFO

  • Officer
No longer subject to file 2018-02-16 0

DEXCEL PHARMA TECHNOLOGIES LTD.

  • 10% Owner
16,013,540 2017-09-06 0

SHABET ROSE SHARON

  • 10% Owner
75,000,000 2017-07-01 0

DEXXON HOLDINGS LTD.

OREN DAN

  • 10% Owner
37,231,342 2016-10-26 0

VIKING GLOBAL INVESTORS LP

VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

VIKING GLOBAL OPPORTUNITIES GP LLC

HALVORSEN OLE ANDREAS

OTT DAVID C.

SUNDHEIM DANIEL S.

  • 10% Owner
37,231,342 2016-10-26 0

ABRAMS MICHAEL J. MANAGING DIRECTOR

  • Officer
No longer subject to file 2016-09-30 0

HIGGINS PATRICK T. CHIEF BUSINESS OFFICER

  • Officer
No longer subject to file 2016-04-30 0

JEWELL DONALD GORDON

  • FORMER DIRECTOR
No longer subject to file 2015-03-04 0

GARDINER DIANE

  • FORMER VP, HUMAN RESOURCES
No longer subject to file 2015-03-04 0

BRENNAN PAUL A. SR VP, BUSINESS DEVELOPMENT

  • Officer
No longer subject to file 2015-03-04 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MCELHAUGH MICHAEL J. - Officer CHIEF BUSINESS OFFICER

2020-07-23 S 20,000 $5.01 d 1,367,457 1,367,457.00 direct yes
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments